Showing 7261-7270 of 20895 results for "".
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://reachmd.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- Could a Dietary Fiber Supplement Offer Long-Awaited Treatment for Food Allergy Sufferers?https://reachmd.com/news/could-a-dietary-fiber-supplement-offer-long-awaited-treatment-for-food-allergy-sufferers/2467292/A study from the University of Michigan has identified a potential new treatment for food allergies in inulin, a naturally occurring plant fiber commonly used as a supplement, a prebiotic in soda, a replacement for sweeteners and for other products and purposes.
- Most Consumers Lack Familiarity with U.S. Farm Bill Now Under Considerationhttps://reachmd.com/news/most-consumers-lack-familiarity-with-us-farm-bill-now-under-consideration/2467317/Bill contains provisions that receive bipartisan public support WEST LAFAYETTE, Ind. — The general public has limited knowledge of the U.S. farm bill that politic
- Study Finds New Program Streamlined Hospice Transitions from the Emergency Departmenthttps://reachmd.com/news/study-finds-new-program-streamlined-hospice-transitions-from-the-emergency-department/2467280/Credit: Pixabay/CC0 Public Domain For patients who are in the final stages of both gradual and sudden terminal illnesses, ho
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://reachmd.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- New Molecular Signatures Found for Alzheimer’s Diseasehttps://reachmd.com/news/new-molecular-signatures-found-for-alzheimers-disease/2467273/Summary: Researchers identified unique molecular signatures of blood-brain barrier dysfunction in Alzheimer’s disease. They discovered altered communication between brain vascular cells mediated by VEGFA and SMAD3 molecules. These findings could lead to new diagnost
- Association Between Vitamin D Status and Thyroid Cancer: A Meta-Analysishttps://reachmd.com/news/association-between-vitamin-d-status-and-thyroid-cancer-a-meta-analysis/2467269/1 Introduction Thyroid cancer (TC) is the most common malignancy of the endocrine system, encompassing three overarching histological classifications: differentiated, medullary and anaplastic thyroid cancer (
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://reachmd.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- Older Women Are Different Than Older Men. Their Health Is Woefully Understudiedhttps://reachmd.com/news/older-women-are-different-than-older-men-their-health-is-woefully-understudied/2467257/Medical research has shortchanged women for decades. This is particularly true of older women, leaving physicians without critically important information about how to best manage their health. Late last year, the Biden administration pr
- Popular Prescription Weight Loss Drugs Linked to Uncommon Blinding Conditionhttps://reachmd.com/news/popular-prescription-weight-loss-drugs-linked-to-uncommon-blinding-condition/2467260/A new Mass Eye and Ear-led study is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a form of blindness due to optic nerve disease known as non-arteritic anterior ischemic optic neuropathy (NAION). <